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Summary
The increasing use of orthopedic implants and, in particular,
of hip and knee joint replacements for young and active pa-
tients, has stimulated interest and concern regarding the ch-
ronic, long-term effects of the materials used. This review fo-
cuses on the current knowledge of the adverse biologic reac-
tions to metal particles released from orthopaedic implants in
vivo and in vitro. More specifically, the purpose of this article
is to provide an overview of the current literature about the ad-
verse effects of metal particles on bone cells and peri-implant
bone.
KEY WORDS: orthopaedic implants; metal ions; adverse effects; bone cells;
osteolysis.
Introduction
Over the last 30 years, orthopaedic surgery has immeasurably im-
proved the lives of millions of people, restoring their mobility, bring-
ing pain relief and ultimately giving them a better quality of life. The
main orthopaedic implants currently in use are prostheses for re-
placing arthritic joints, and devices for fixing fractures and stabiliz-
ing the spine. Joint replacement, and in particular knee and hip re-
placement, has arguably seen the greatest advances in terms of in-
vestment, research and clinical results. Prosthetic joint replace-
ment has proved to be a highly reliable treatment even in the long
term (1). However, in spite of the success of this type of surgery,
there still remains the need for further progress; average life-ex-
pectancy is rising which necessitates ever more long-lasting implants,
and complications and adverse effects are not infrequent (1)and of-
ten require the substitution of the prosthesis. Furthermore, it is gen-
erally accepted that within 15-20 years after surgery, aseptic loos-
ening of the implants is almost inevitable. If infection is excluded,
the most frequent complication associated with joint replacement is
the deterioration of the prosthetic components and the resulting bio-
logical response of the body to the material released by the implant.
Thus the generation of wear debris and the subsequent tissue re-
action to this debris, have a fundamental effect on the longevity of
total joint arthroplasties.  Although adverse reactions to implants are
relatively rare, if we take into account the huge number of prosthe-
ses implanted to date and the hundreds of thousands of new pros-
theses implanted each year, the problem could potentially be huge.
The situation has become more urgent with the increasing number
of reports of adverse effects related to metal ion release from cer-
tain types of hip prosthesis, in particular those which have direct con-
tact between two metal joint components (MoM: metal-on-metal).
As these prostheses have mechanical characteristics which are par-
ticularly attractive, they have been widely used over the last few years,
particularly in younger patients.
Whilst adverse reactions to metals have been studied for many years
by pathologists, toxicologists, company doctors and dermatolo-
gists, research has begun relatively recently in Orthopaedics, and
therefore the results are limited. The toxicokinetics of small metal
wear particles and associated corrosion products remain unclear,
and data are particularly scarce regarding the effect of metal ions
on bone cells and bone resorption (osteolysis). In light of this lack
of data and the emerging problems in the field of orthopaedic im-
plants, we have carried out a review of the literature on the adverse
effects of metal ion release. The purpose of this review is to provide
a comprehensive update on the effects of metal ions on bone cells
and bone resorption after a surgical orthopaedic implant.
Orthopaedic biomaterials
The principal characteristic required by biomaterials if they are to
be used in orthopaedic surgery is that they are resistant to re-
peated mechanical stress. Only metals, ceramics and polymers
meet this fundamental requirement (Table 1).
Metals
Amongst the orthopaedic biomaterials currently in use, only met-
als provide a combination of additional advantages: high strength,
ductility, tenacity, hardness, fracture toughness, corrosion resis-
tance, formability and biocompatibility. Although initial prosthet-
ic designs used stainless steel, over the years the metal alloys
developed in the aeronautical and naval industries were adopt-
ed for use in Orthopaedics.  
The three main metal alloys used in the production of joint pros-
theses are the following: stainless steel based alloys; cobalt al-
loys; and titanium alloys. Each of these alloys has its own par-
ticular strength, rigidity and ductility properties. However, their high
resistance to corrosion has made them particularly suitable for use
in the manufacture of orthopaedic implants.
Current technology in total hip and knee arthroplasty
The vast majority of joint arthroplasties are performed either in the
hip or the knee. The materials used for the prosthetic components
are more or less similar for the two joints. Currently, hip prostheses
tend to comprise a titanium or cobalt-chromium alloy femoral
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stem, either cemented with PMMA or press fitted, which is con-
nected to a cobalt-chromium alloy or ceramic head. The head ar-
ticulates with a UHMWPE or ceramic or cobalt-chromium cup lin-
er, which is cemented, screwed or press fitted into the acetabu-
lum. In younger patients the preferred design is ceramic-on-ce-
ramic or metal-on-metal (MoM) due to the greater longevity of
these implants. The most widely-used metal implants are chromi-
um-cobalt-molybdenum and cobalt-nickel-chromium-molybde-
num, then titanium alloys, and recently new zirconium and tan-
talum alloys. This may account for the fact that there are many
more studies published about the effects of chromium and cobalt
than those regarding the effects of other ions.
Orthopaedic biomaterial degradation
Orthopaedic biomaterials are associated with local and remote
adverse tissue responses. Generally, these adverse effects are
mediated by the degradation products of implanted materials,
which are primarily generated by wear and corrosion. This debris
can be present in different forms: free metallic ions; colloidal
complexes; inorganic metal salts or oxides; organic forms (such
as hemosiderin); and finally, wear particles. 
Particulate debris has a very large surface area with which to in-
teract with surrounding tissues, and this is confirmed by the
chronically elevated levels of metal content in serum and urine
found in patients who have received a metal implant. The par-
ticulate debris that is generated by wear, fretting and fragmen-
tation, and which is unavoidable when a prosthesis is implanted,
can induce an inflammatory reaction in some circumstances.
This, at a certain point, promotes a foreign-body granulation tis-
sue response that is able to invade the interface between bone
and implant. This results in progressive local osteolysis that
threatens the fixation of the hardware (2).
Whilst polyethylene degrades through wear alone, the metal al-
loys used in orthopaedic implants also degrade due to corrosion,
or a combination of wear and corrosion (3, 4).
Wear
Two materials placed together under load develop electrorepul-
sive and atomic binding interactions in the area of contact. When
the surfaces slide across each other, these reactions are disrupted,
and particles of material (wear debris) are generated. These par-
ticles may attach to the counter face, remain between the two sur-
faces or disperse into the system of the host.  
The rate of wear depends largely on the contact force between
the two surfaces and the sliding distance, and thus increases with
physical activity, weight gain, larger implants and the roughness
of the implant surface (5). Every step that a patient takes creates
a loading cycle that can potentially cause wear of the bearing sur-
faces, even in an optimally designed and implanted prosthesis. 
Corrosion
All metallic surfaces undergo electrochemical corrosion that re-
duces the structural integrity of the implant and releases products
of degradation that are potentially toxic to the host. The mecha-
nism of corrosion is essentially the galvanic effect, based on the
thermodynamic driving forces which cause an oxidation/reduction
reaction. Every metal has its own reactivity to oxidation and the
exposure of metal to synovial or organic fluids produces a gra-
dient-based exchange of electrons and ions (cations) from the met-
al to the solution, whereas oxygen anions from the watery solu-
tion tend to migrate into the implant.
Results of metal degradation
The main products of metal degradation are metal oxides (i.e. CoO)
and hydroxides [i.e. Cr (OH)
3
] that can be found within the synovial
environment, and metal phosphates (i.e. CrPO
4
) that are gener-
ally deposited in the extra-synovial tissues. Compared with poly-
ethylene debris, metal particles are markedly smaller (<50nm vs.
>0.1 µm) and more numerous (up to 13,500 times more in MoM
hip arthroplasties) (6). Moreover, particle size and shape changes
with the severity of wear and the passage of time, as corrosion is
a continuous process (7, 8). As the size of the particle decreas-
es, the cumulative surface area increases, with more atoms ex-
posed and a greater biological activity per given mass compared
to larger particles (7). 
Owing to their small size, nanoparticles are ingested by
macrophages or disseminate systemically via lymphatics to lymph
nodes, bone marrow, liver and spleen (9). Further corrosion re-
leases metal ions which enter the bloodstream and become con-
centrated in the erythrocytes. Thus, metal ions may enter cells and
remain in local tissues or they can be transported throughout the
body, which can lead to cytotoxic, genotoxic and immunological
effects, either locally or at distance from the implant (10). 
Metal nanoparticles can pass through the cell plasma membrane
mainly by diffusion or endocytosis (7). Diffusion can occur directly
or through membrane channels, whereas endocytosis uses a
receptor-mediated mechanism. The latter conveys 200nm or
smaller metal nanoparticles, with a preference for 50 nm metal
particles which are taken up faster and more extensively than
smaller (≥ 14nm) and larger (≤ 500nm) particles (7, 11, 12). An-
other doorway for small particles is via pinocytosis, a less spe-
cific form of endocytosis. Larger fragments are taken up by phago-
cytic processes of specialized cells such as macrophages (13).
Inside the cells, the particles are exposed to oxidative attacks
Table 1 - Orthopaedic biomaterials.
Material Use
Metals Titanium alloys (Ti-6%, Al-4%V) Plates, screws, prosthetic components
Cobalt-chromium-molybdenum alloys (Co-Cr-Mo) Prosthetic components
Stainless steel Plates, screws, cerclage wire, prosthetic  components
Polymers Polymethyl methacrylate (PMMA) Bone cement
Ultra-high-molecular-weight-polyethylene (UHMWPE) Prosthetic inserts
Ceramics Aluminium oxide (AlO
2
) Prosthetic surfacing
Zirconium (ZrO
2
) Prosthetic surfacing
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which are intended to destroy the foreign body, but result in the
generation of metal ions and free radicals (mainly reactive oxy-
gen and reactive nitrogen species). The cytotoxic effect is exert-
ed by means of oxidative stress and chromosomal damage. Re-
active oxygen species derived from Cr, Ni, Co and Ti may cause
oxidative damage to the nucleus, proteins and lipids.  This results
in inhibition of DNA repair pathways, impaired nuclear signal
transduction and defective gene expression (14). With most cy-
totoxic agents such as Ti, Co and V, apoptosis or necrosis oc-
curs in some cells (15). 
Many studies report elevated Cr and Co ion levels in blood and
urine. Rates of wear can be assessed by evaluating ion levels in
red blood cells, although serum gives a better estimate of the true
systemic levels (16). Renal excretion of metal ions seems to bal-
ance their generation in patients with MoM hip arthroplasties
(17), although levels of circulating Co and Cr ions remain sever-
al times above the normal levels. An approximately 5- to 10-fold
increase from preoperative to postoperative values in blood Co
levels has been shown in several series with different implants
(18-21). Although elevated, these concentrations are well below
the limits considered dangerous to health in workers exposed to
industrial chemicals, and also lower than the levels found to
cause cell toxicity in vitro (22). 
Systemic effects of metal ions
Most in vitro and in vivo studies that have been published in the
Literature are related to the effects induced by Cr and Co. Oth-
er known potential toxic ions released by orthopaedic implants are
Titanium (Ti), Aluminum (Al), Vanadium (V) and Nickel (Ni). Co,
Cr and possibly Ni and V are normal components of some en-
zymes of our body. They must be introduced with the diet, but be-
come toxic at high dosage.
Co toxicity can affect many organs, and can cause various
types of symptoms: neurological (tinnitus, vertigo, deafness,
blindness, convulsions); cardiological (cardiomyopathy);
haematological (polycythemia); and endocrine (hypothy-
roidism). Cr seems to be less cytotoxic but more genotoxic
than Co (13, 23). It induces tubular necrosis and interstitial cell
damage which can result in impaired renal functioning (24). Al-
so potentially severe hepatic lesions have been described, with
hepatocellular necrosis and possibly disseminated intravascu-
lar coagulation (25). As observed in experimental studies, Cr
may compete with Fe in binding to apo-transferrin, causing
anaemia. Chronic exposure to Cr has detrimental effects on
male and female fertility as a result of decreased sperm pro-
duction and impaired sperm and ova quality (26).
Al toxicity has been linked to neurological conditions such as
memory loss, gait disturbance and involuntary movement, and
the development of neuropathological conditions such as amy-
otrophic lateral sclerosis. Moreover, the accumulation of Al in
the brain has been reported as a possible cause of Parkinson’s
disease, dialysis encephalopathy and Alzheimer’s disease (27-
29). Chronic Al exposure has been related to osteomalacia,
pathological fractures, impaired bone remodelling, altered re-
sponse to vitamin D and proximal myopathy (30).
In rats, intra-articular injected TiO
2
nanoparticles caused toxi-
cological effects on the lungs with follicular lymphoid hyperpla-
sia and inflammatory cells aggregated around the bronchia
(31).
High concentrations of Al, Co and Ni may cause severe retinal
degeneration in experimental animals (32).
Ionic Cr, Co, Ni, V, Al and Ti have mutagenic actions on cells in
tissue culture. The genotoxic effects of the metal ions are
thought to be mediated by either direct action, causing DNA
breaks through attacks on free radicals, or by an indirect effect
inhibiting the repair of DNA (33).
Local effects of metal ions
Hystological studies performed on peri-implant soft tissues tak-
en at the moment of hardware retrieval, showed an inflammato-
ry response all around the implant. In the presence of relatively
large debris particles, the reaction is mainly due to macrophages.
In the case of small nanoparticles, the inflammatory process
seems to be more a cell-mediated hypersensitivity reaction (34).
Patients with metal orthopaedic implants have not only elevated
serum Co and Cr concentrations (as mentioned above) but also
significantly elevated lymphocyte reactivity to Co and Ni (34). Lym-
phocyte reactivity is even greater in patients with MoM hip arthro-
plasties, supporting the hypothesis that lymphocyte metal-in-
duced reactivity increases with increased metal exposure. 
The pattern of inflammation in the peri-prosthetic tissue of loose
MoM prostheses is significantly different from that of other im-
plants, and is characterized by an unusual lymphocytic perivas-
cular infiltration and plasma cells accumulation. Histological find-
ings support a lymphocyte-dominated immunological response
with diffuse and perivascular infiltrates of T and B lymphocytes
and plasma cells, massive fibrin exudation, accumulation of
macrophages, infiltrates of eosinophilic granulocytes and necro-
sis. There are usually only few metal particles (35-38). On the oth-
er hand, tissue samples obtained from hip arthroplasties with con-
ventional implants show no pattern of lymphocytic infiltration and
no plasma cells. The inflammation is predominantly histiocytic. 
In the presence of a cell-mediated reaction, a lymphocytic re-
sponse to serum protein complexed with metal from implant al-
loy degradation products has been demonstrated (39).
In some cases the inflammatory reaction can be particularly ag-
gressive and periprosthetic soft-tissue masses (pseudotumours,
i.e. soft-tissue mass relating to the joint) can be found in patients
with MoM hip resurfacing. These periprosthetic soft-tissue le-
sions have been described variously as metallosis, aseptic lym-
phocytic vasculitis-associated lesions (ALVAL), adverse reac-
tion to metal debris (ARMD) and pseudotumours. The occur-
rence of such soft tissue reactions is rare, although the number
of reports seems to be increasing (40-42). These reactions are
locally destructive, requiring revision surgery in the majority of pa-
tients. Macroscopically there is a large amount of pericapsular met-
al debris in the soft tissues which are stained (metallosis) and em-
bedded with dark metal debris. Incision of the capsule reveals a
copious amount of black, tar-like joint fluid. Often there is a syn-
ovial-like biomembrane with the capacity to produce collage-
nase, interleukin 1, and tumour necrosis factor which may medi-
ate the absorption of peri-implant bone. The inflammatory mark-
ers are usually normal, whereas the serum Co and Cr ion levels
are significantly higher than usual (6-7 times more than in patients
with the same implant but without pseudotumours) (43).
Effects on osteoblasts
Although osteolysis is the main feature of peri-implant aseptic loos-
ening, bone resorption may not be the only cause of bone loss.
It is well known that normal bone turnover involves a balance be-
tween bone formation and bone resorption. The net loss of peri-
implant bone may be the result of a reduction in bone formation,
with or without a concomitant increase in bone resorption. The
relationships between wear debris and bone resorption have
been intensely studied, whereas much less is known about the
effects of particulate debris on the growth and metabolism of os-
teoblastic cells. However, it seems relatively well established
that metal ions can affect the function of osteoblasts and os-
teoblast-like cells (44-46).
Cytotoxicity has been demonstrated in osteoblast cultures ex-
posed to metallic wear debris, although the metal ion concen-
trations within bone in vivo have not been established (47, 48).
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Metal cytotoxicity, which may ultimately lead to cell death, can
cause significant morphological changes, damage to proteins,
and modified protein expression. Morphological changes have
been observed after osteoblasts have been exposed to Co par-
ticles at concentrations of 100 μg/L or higher with the develop-
ment of cytoplasmic vacuolations (44-46). Proteins from the ex-
tracellular matrix such as bone sialoprotein, osteocalcin, and
osteopontin are important for calcification of the bone matrix
and can be used as markers of osteoblastic activity. These
proteins are synthesized by osteoblasts and released into the
extracellular matrix. Millett et al. observed that the levels of os-
teocalcin in synovial fluid are lower in patients undergoing revi-
sion for aseptic loosening compared with those having primary
hip arthroplasty (49). They hypothesised that the osteoblasts
lining the joint space are less active, which is possibly due to
an inhibitory effect of particulate wear debris. Other Authors
demonstrated that Co and Cr inhibit the release of osteocalcin
into the bone matrix in vitro, contributing to the delay in miner-
alization of bone tissue following exposure to metal (50-52).
Another indirect sign of the dysregulation of the osteoblast-like
cells induced by metals is the pronounced reduction of alkaline
phosphatase activity observed after exposure to Co and Cr
ions (53, 54). Also collagen type I synthesis is markedly re-
duced after exposure to Co and Cr particles or ions at concen-
trations of 10 μg/L or 100 μg/L (45, 55, 56). A decrease in pro-
tein, DNA, and RNA synthesis has been shown with Co and Cr
ions (57). This is most significant with a cytotoxic metal, such
as cobalt, which kills the osteoblastic cell and eliminates the
source of the marker proteins.
Studies in vitro showed that osteoblasts exposed to Co and Cr
ions undergo a time- and dose-dependent reduction in prolifera-
tion (54). Metal ions differentially affected osteoblast proliferation,
viability, type-I collagen gene expression, and cytokine release.
A ranking of the least to the most toxic metal ions (based on a
50% reduction in viability) reads as follows: Na < Cr < Mg < Mo
< Al < Ta < Co < Ni < Fe < Cu < Mn < V.  Metal-induced decreases
in osteoblast proliferation are similar in ranking (46). 
Beyond reduction in the number of cells, microscopic analysis has
also demonstrated changes in cell shape and size. Co+2 had a
greater effect on these parameters than Cr+3. Cell counting
showed a significant decrease in the number of osteoblasts, with
Co+2 again more toxic than Cr+3. Also the redox state of os-
teoblasts was altered, with oxidation and nitration of proteins and
dysregulation of the expression of antioxidant enzymes (54).
Finally, in the presence of metal ions osteoblasts are able to
release proinflammatory cytokines into the microenvironment,
such as transforming growth factor beta 1 (TGF-b1), tumour
necrosis factor alpha TNF-α, interleukin beta 1 (IL-b1) and,
most commonly, IL-6 (45, 46). These cytokines can in turn, ac-
tivate the differentiation of preosteoclasts into mature bone re-
sorbing cells (58).
Effects on osteoclasts
It is still not clear how metal ions act on osteoclasts, and the ion
quantity required to cause an adverse effect, as the results of pub-
lished studies are somewhat contradictory. Probably, the effects
of metal ions vary according to the state of differentiation of the
cells and to the concentration of metal ions.
Osteoclasts are highly specialized multinucleated cells that are
responsible for lacunar bone resorption. Osteoclast precursors are
mononuclear, bone-marrow-derived cells that are included in the
monocyte fraction of blood cells. The classical osteoclast differ-
entiation and activation pathway requires the presence of the os-
teoblastic macrophage-colony stimulating factor (M-CSF) and
necessitates an interaction between the receptor activator of nu-
clear factor kappa B (RANK), which is expressed on osteoclast
precursors, and RANK ligand (RANKL), which is expressed by os-
teoblasts and several other cells.
It has recently been shown that some proinflammatory cy-
tokines, such as tumour necrosis factor-alpha  (TNF-α), IL-6
and IL-11 are able to induce osteoclast formation from bone
marrow cells and circulating precursors through a RANKL-inde-
pendent mechanism (58).
Another substance implicated in several bone conditions with
localized or generalized pathological bone resorption is the
TGF-β. It has been found in large amounts in synovial fluid in
rheumatoid arthritis where marginal bone erosions are almost
always observed. TGF-β serum levels are also elevated in
case of osteolytic tumours with hypercalcaemia and in osteo-
porotic women. A RANKL-independent induction of human os-
teoclasts has been demonstrated also for TGF-β. Thus, it may
play a role in these osteolytic conditions, which are associated
with increased cytokine production (59).
Particle uptake by macrophages and metal ion effects on os-
teoblasts influence the production of M-CSF and RANKL as
well as elicit the production of proinflammatory cytokines (IL-1,
IL-6, IL-11, TNF-α), prostaglandins (PGE+2) and TGF-β. It is
likely that this can have a significant impact on osteoclast activ-
ity (60, 61). Although both MCSF and RANKL have been identi-
fied as key players in osteoclast differentiation and activation,
recent studies suggest these factors may also play a role in os-
teoclast survival. For example, RANKL has been demonstrated
to be an essential factor in the maintenance of osteoclast via-
bility in vitro. MacQuarrie et al. (2004) (62) observed that Ti
and CoCr particles induced osteoclast apoptosis, whereas Co
and Cr stimulated osteoclast differentiation. After the addition
of anti-RANKL antibodies to the Co and Cr cultures, the num-
ber of cells significantly decreased. However, the Authors used
metal particles close to the size of polyethylene debris, which
is able to induce the macrophage response that is usually ab-
sent with nanoscale metal particles.
In vitro experiments have shown that Co ions induce the death
of osteoclast precursors after 2 weeks. After 3 weeks, there
was a decrease in the area of resorbed dentine, indicating a
toxic effect of Co on pre-osteoclasts (63). Rousselle et al. in-
vestigated the effects of metal ions on mature osteoclasts iso-
lated from the long bone of rabbits, and reported that although
Co and Cr did not induce apoptosis of mature osteoclasts, co-
culture with Co ions decreased their size (64).
In vivo data suggest that the concentrations of Co and Cr ions
reported in serum and hip synovial fluid of patients with MoM
implants have an effect on human osteoclasts. These ions
have a mild stimulatory effect on developing osteoclasts, but
have an inhibitory effect on mature osteoclasts at higher con-
centrations (equivalent to the levels found in synovial fluid)
(65). The reason for this difference might be explained by the
substrate resorbing activity of the cells and the dose-related
toxicity of metal ions. Metal ions such as Co+2 which are pre-
sent in serum, synovial fluid and peri-implant tissues, can also
be incorporated into the mineral phase of bone development.
Mature osteoclasts accumulate more intracellular metal ions
through their resorbing phagocytic activity in comparison to im-
mature osteoclasts, with a greater toxic effect (65).
Another study has shown that Co ions in solution or incorporat-
ed into calcium phosphate at clinically relevant concentrations,
increase murine osteoclast differentiation and resorption activi-
ty in vitro (66). Authors observed a maximal 75% increase in
osteoclast numbers and a 2.3- to 2.7-fold increase in mineral
resorption from the tissue culture wells, at concentrations simi-
lar to those found in serum and in peri-implant tissues in vivo.
This direct effect of Co+2 on osteoclasts appears to act inde-
pendently of the particulate phagocytosis/inflammation-mediat-
ed pathways, thus enhancing osteolysis and, possibly, aseptic
implant loosening.
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Effects on bone resorption (osteolysis) 
The effects of metal particles on bone cells and bone resorption
is a crucial issue for orthopaedic implant durability. In orthopaedic
implants, the most frequent manifestation of local osteolysis is re-
ported with hip arthroplasties. The knee seems to be less vul-
nerable, but it is unclear why. Probably, the different mechanical
loading, with consequent different mechanisms of wear, and a
more effective barrier to debris migration at bone-implant inter-
face, can account for this disparity. 
It is well known that normal bone maintenance relies on the bal-
ance of bone formation and resorption which implies coordinat-
ed activity of osteoblasts and osteoclasts. Thus, either a reduc-
tion of osteoblastic bone formation or an increase in osteoclas-
tic bone resorption can lead to a net bone loss (i.e. osteolysis).
Osteolysis around an implant is the main concern for the or-
thopaedic surgeon and it is seen either as diffuse cortical thin-
ning (Figure 1) or as a focal cyst-like lesion (Figure 2). The phe-
nomenon was initially attributed to a reaction to bone cement (poly-
methyl methacrylate). However, later observations that osteoly-
sis can be found also in association with well-fixed or loose un-
cemented implants, disproved this hypothesis. 
According to some Authors, periprosthetic osteolysis is a cellu-
lar inflammatory reaction to wear debris (67). As previously said,
there are numerous secretory products generated by the cells
around implants that can negatively affect bone turnover, such
as TNF-α, TGF-β and pro-inflammatory cytokines (i.e. IL-1 and
IL-6). Some of these, such as IL-10, can even modulate the
process. Other factors involved with bone resorption are obviously
the enzymes responsible for catabolism of the organic con-
stituents of bone tissue, such as stromelysin and collagenase ma-
trix metalloproteinases. Prostaglandins, especially PGE+2, act as
intercellular messengers in the osteolytic process induced by
metal debris. PGE+2 and other bone-resorbing factors such as col-
lagenase, can be produced in large amounts also by the cells of
the membrane at bone-implant interface in patients with a loose
implant. Moreover, recent research shows that several mediators
involved in stimulation/inhibition of osteoclast differentiation and
maturation, such as RANKL and osteoprotegerin can play a key
role in the triggering and progression of bone loss (68). 
A higher rate of hypersensitivity reactions to cobalt skin testing
has been observed in patients with peri-implant osteolysis com-
pared to controls without osteolysis, indicating a delayed-type hy-
persensitivity reaction (69). The histological and immunohisto-
chemical examination showed a perivascular accumulation of T
lymphocytes and elevated levels of bone-resorbing cytokines
(i.e. IL-1 and TNF-α) produced by infiltrating lymphocytes and ac-
tivated macrophages. Even though a causal relationship could not
be established from the study, these findings suggest that early
osteolysis is associated with abnormalities consistent with delayed-
type hypersensitivity to metal. Granchi et al. observed that the nor-
mal implant lifespan of a total hip replacement, which averages
120 months, is reduced to 78 months in patients testing positive
and/or with a history of allergic contact dermatitis caused by met-
als (70). Moreover, a significant increase (6.5%) of metal sensi-
tization one year after the implant has been reported (71).
Although allergy can play a significant role, the question remains
Figure 1 - Diffuse cortical thin-
ning due to bone resorption
around a hip stem (cortical thin-
ning indicated by white arrows). 
Figure 2 - A clearly-deﬁned osteolytic area around the acetabular com-
ponent of a hip prosthesis.
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largely unanswered as to why only some patients with an or-
thopaedic implant experience early osteolysis and occasionally,
early implant loosening, whereas the majority of patients with the
same implant show no radiological sign of peri-implant bone re-
sorption and have an excellent and lasting clinical outcome. As
previously said, metal particle release is a feature common to all
patients who have an orthopaedic metal implant. The likelihood
of osteolysis has been correlated with the amount of wear parti-
cles (72); the generation of wear particles depends on many fac-
tors including the properties of the implant, surgical accuracy
and patient characteristics (73). Engh et al. estimated that wear
and patient predisposition to osteolysis may together account for
53% of the variance in the total area of osteolysis (74). Recent-
ly, the concept of “individual susceptibility” to periprosthetic os-
teolysis has been introduced (75). This concept postulates that
the local tissue homeostatic mechanisms more effectively regu-
late the inflammatory/osteolytic response in patients with no/slight
peri-implant osteolysis than those with severe osteolysis. The
homeostatic mechanism acts through a variety of cytokines,
chemokines, hormones and specific cell populations, including
macrophages, dendritic and stem cells, which attempt to main-
tain tissue architecture, to balance adverse reactions and mini-
mize inflammation. Seen from this point of view, osteolysis is a
sort of failure of local tissue homeostatic mechanisms.
Although the complete pathway is far from being understood, it
seems clear that osteolysis is the result of a complex host re-
sponse to chronic exposure to implant debris. It is a multi-facto-
rial process, dependent on implant design, material composi-
tion, surgical technique and, probably the most important, patient
factors.
Conclusions
Research into the biocompatibility of orthopaedic materials is
becoming ever more important as the use of implants steadily in-
creases, the expectations of implant longevity and performance
grow, and as new implants are developed and marketed. The el-
evated metal body content found in the body fluids and remote
organs of patients with metal implants is a matter of fact, but its
clinical significance needs further elucidation. The effects of met-
al particles on bone cells and bone resorption is a crucial issue
for orthopaedic implant durability but, again, available data are
still incomplete. However it seems clear that osteolysis is a mul-
ti-factorial process, dependent on implant design, material com-
position, patient factors and surgical technique. In order to reduce
peri-implant osteolysis and to lengthen the lifespan of orthopaedic
implants, considerably more research will be required to under-
stand the specific chemical forms and distribution of metal degra-
dation products, and their effects on human cells and tissues. 
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